Omeros CorporationOMER stock score: 57/100

$14.01 · -3.71% · Scored Nov 19, 2026

Technical
53
Fundamental
58
News
52

The reading

Omeros (OMER) scores 57 out of 100, which reads neutral, higher than 69% of Healthcare stocks and 68% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 58, technicals 53.

Among the fundamentals, Price Target at 100 and Profit Margins at 100 score highest, while Earnings Quality (Annual) at 0 weighs the most against it.

On the daily chart, trend-following indicators average 26 and contrarian oscillators 71 — a split worth reading before trusting the technical total.

News sentiment is neutral at 52; it is shown, not counted in the composite.

Since Aug 23, 2026 the composite has ranged from 53 to 61, and it is down 3 points over the period.

About Omeros

Omeros (OMER) is a biopharmaceutical company focused on drugs that target the complement system, part of the immune system. Its first approved product, Yartemlea (narsoplimab), is an antibody that blocks a key enzyme of the lectin pathway of complement. The FDA approved it for hematopoietic stem cell transplant-associated thrombotic microangiopathy, a serious complication of stem cell transplants, in adults and children, and the company has also sought approval in Europe. Omeros sells Yartemlea to transplant centers and hospitals in the United States, and those sales are its main source of product revenue. The company sold global rights to zaltenibart, a complement inhibitor for rare blood and kidney diseases, to Novo Nordisk for an upfront payment plus potential milestones and royalties. It funds earlier-stage programs from product sales, deal proceeds and capital raised from investors.

In transplant-associated thrombotic microangiopathy, Yartemlea competes mainly with off-label use of complement inhibitors from AstraZeneca’s Alexion unit, along with supportive care. Its edge rests on being the first approved therapy for the condition, a mechanism that targets the lectin pathway specifically and a label that carries no boxed warning. Investors who follow OMER stock tend to watch the U.S. launch of Yartemlea, including uptake at transplant centers, reimbursement and quarterly sales. Regulatory decisions outside the United States are closely followed. Zaltenibart milestones, debt obligations and cash burn are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward OMER’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

58

Pulling it up

  • Price target score compares the current stock price to analyst consensus targets.

  • Profit margins show what percentage of revenue becomes profit.

  • Net income growth against the same quarter a year earlier, weighted toward the latest quarter.

Holding it back

  • Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.

  • 5-year earnings growth evaluates long-term profit trajectory and consistency.

  • Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.

31 weighted scorers; 8 had no data today and are left out rather than counted as zero.

Technical · daily

32

Pulling it up

  • Bollinger Bands (20-period) plot standard deviations above and below a moving average.

  • Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.

  • The price change over the last 52 weeks.

Holding it back

  • Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.

  • Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.

  • Weighted Moving Average (50-period) tracks the intermediate trend with more weight on recent prices than a simple 50-period average.

62 weighted scorers; 3 had no data today and are left out rather than counted as zero.

News · shown, not counted

Global News
52

Technical score by timeframe

ChartScoreWeight
Hourly331
Daily323
Weekly562
Monthly702
Quarterly742

Composite score, last 90 days

05010057Aug 23, 2026Nov 19, 2026Aug 23, 2026: 60Aug 24, 2026: 61Aug 25, 2026: 60Aug 26, 2026: 59Aug 27, 2026: 60Aug 28, 2026: 59Aug 29, 2026: 59Aug 30, 2026: 59Aug 31, 2026: 59Sep 1, 2026: 59Sep 2, 2026: 60Sep 3, 2026: 60Sep 4, 2026: 60Sep 5, 2026: 60Sep 6, 2026: 60Sep 7, 2026: 60Sep 8, 2026: 60Sep 9, 2026: 60Sep 10, 2026: 57Sep 11, 2026: 57Sep 12, 2026: 58Sep 13, 2026: 58Sep 14, 2026: 56Sep 15, 2026: 56Sep 16, 2026: 57Sep 17, 2026: 59Sep 18, 2026: 58Sep 19, 2026: 57Sep 20, 2026: 57Sep 21, 2026: 58Sep 22, 2026: 61Sep 23, 2026: 61Sep 24, 2026: 60Sep 25, 2026: 60Sep 26, 2026: 60Sep 27, 2026: 60Sep 28, 2026: 58Sep 29, 2026: 58Sep 30, 2026: 58Oct 1, 2026: 57Oct 2, 2026: 56Oct 3, 2026: 57Oct 4, 2026: 57Oct 5, 2026: 58Oct 6, 2026: 57Oct 7, 2026: 58Oct 8, 2026: 59Oct 9, 2026: 60Oct 10, 2026: 60Oct 11, 2026: 60Oct 12, 2026: 59Oct 13, 2026: 58Oct 14, 2026: 56Oct 15, 2026: 56Oct 16, 2026: 54Oct 17, 2026: 54Oct 18, 2026: 54Oct 19, 2026: 54Oct 20, 2026: 54Oct 21, 2026: 54Oct 22, 2026: 54Oct 23, 2026: 55Oct 24, 2026: 54Oct 25, 2026: 54Oct 26, 2026: 55Oct 27, 2026: 56Oct 28, 2026: 58Oct 29, 2026: 59Oct 30, 2026: 57Nov 1, 2026: 57Nov 2, 2026: 57Nov 3, 2026: 59Nov 4, 2026: 58Nov 5, 2026: 54Nov 6, 2026: 53Nov 7, 2026: 53Nov 8, 2026: 53Nov 10, 2026: 55Nov 11, 2026: 57Nov 12, 2026: 61Nov 13, 2026: 60Nov 14, 2026: 59Nov 15, 2026: 59Nov 16, 2026: 58Nov 17, 2026: 57Nov 18, 2026: 58Nov 19, 2026: 57
Show the daily numbers
DateComposite
Nov 19, 202657
Nov 18, 202658
Nov 17, 202657
Nov 16, 202658
Nov 15, 202659
Nov 14, 202659
Nov 13, 202660
Nov 12, 202661
Nov 11, 202657
Nov 10, 202655
Nov 8, 202653
Nov 7, 202653
Nov 6, 202653
Nov 5, 202654
Nov 4, 202658
Nov 3, 202659
Nov 2, 202657
Nov 1, 202657
Oct 30, 202657
Oct 29, 202659
Oct 28, 202658
Oct 27, 202656
Oct 26, 202655
Oct 25, 202654
Oct 24, 202654
Oct 23, 202655
Oct 22, 202654
Oct 21, 202654
Oct 20, 202654
Oct 19, 202654
Oct 18, 202654
Oct 17, 202654
Oct 16, 202654
Oct 15, 202656
Oct 14, 202656
Oct 13, 202658
Oct 12, 202659
Oct 11, 202660
Oct 10, 202660
Oct 9, 202660
Oct 8, 202659
Oct 7, 202658
Oct 6, 202657
Oct 5, 202658
Oct 4, 202657
Oct 3, 202657
Oct 2, 202656
Oct 1, 202657
Sep 30, 202658
Sep 29, 202658
Sep 28, 202658
Sep 27, 202660
Sep 26, 202660
Sep 25, 202660
Sep 24, 202660
Sep 23, 202661
Sep 22, 202661
Sep 21, 202658
Sep 20, 202657
Sep 19, 202657
Sep 18, 202658
Sep 17, 202659
Sep 16, 202657
Sep 15, 202656
Sep 14, 202656
Sep 13, 202658
Sep 12, 202658
Sep 11, 202657
Sep 10, 202657
Sep 9, 202660
Sep 8, 202660
Sep 7, 202660
Sep 6, 202660
Sep 5, 202660
Sep 4, 202660
Sep 3, 202660
Sep 2, 202660
Sep 1, 202659
Aug 31, 202659
Aug 30, 202659
Aug 29, 202659
Aug 28, 202659
Aug 27, 202660
Aug 26, 202659
Aug 25, 202660
Aug 24, 202661
Aug 23, 202660

Key facts

Market cap
$1.0B
Sector
Healthcare
Industry
Biotechnology
Beta
2.99
Risk grade (1–10)
8
Next earnings
Nov 16, 2026

Questions

What is OMER's stock rating today?

OMER scores 57/100 (Neutral) as of Nov 19, 2026: technical 53, fundamental 58, and news sentiment 52, which is shown but not counted. Scores are recomputed every night.

What does Omeros do?

Omeros (OMER) is a biopharmaceutical company focused on drugs that target the complement system, part of the immune system. Its first approved product, Yartemlea (narsoplimab), is an antibody that blocks a key enzyme of the lectin pathway of complement.

Is OMER stock a buy?

The score is not a buy or sell recommendation. A 57 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the OMER score calculated?

93 weighted scorers feed it today: 31 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

OMER stock score

HTML

<a href="https://stocksscores.com/stocks/omer/"><img src="https://stocksscores.com/stocks/omer/badge.svg" alt="OMER stock score" height="20"></a>

Markdown

[![OMER stock score](https://stocksscores.com/stocks/omer/badge.svg)](https://stocksscores.com/stocks/omer/)